32190-95-7Relevant academic research and scientific papers
Glucosides from MBOA and BOA detoxification by Zea mays and Portulaca oleracea
Hofmann, Diana,Knop, Mona,Hao, Huang,Hennig, Lothar,Sicker, Dieter,Schulz, Margot
, p. 34 - 37 (2006)
Incubation of Zea mays cv. Nicco seedlings with 6-methoxybenzoxazolin-2(3#) -one (MBOA) led to a minor detoxification product hitherto only found in Poaceae. This new compound was identified as 1-(2-hydroxy-4-methoxyphenylamino)- 1-deoxy-β-glucoside 1,2-c
2-[(trifluoroacetyl)amino]benzoquinone and the hydrochloride and perchlorate salts of 2-aminohydroquinone
Wiedenfeld, David,Minton, Mark,Nesterov, Vladimir,Montoya, Christine
, p. 95 - 101 (2004)
Hydrogen bonding parameters for the title materials are reported. 2-[(trifluoroacetyl)amino]benzoquinone crystallizes in the monoclinic space group P21/c, with a = 18.195(4), b = 5.110(1), c = 9.635(2), β = 104.22(3)°, V = 868.4(3) A3, and Z = 4. This compound exhibits two weak intramolecular hydrogen bonds. The first is between a hydrogen atom of the quinone ring and the carbonyl oxygen of the trifluoroacetamide group; it has a distance of 2.24 A and a C-H ... O angle of 122°. The second is between the hydrogen atom of the trifluoroacetamide group and a quinone carbonyl group; it has a distance of 2.26 A and a N-H ... O angle of 107°. 2-Aminohydroquinone hydrochloride crystallizes in the orthorhombic space group Pca21, with a = 16.220(3), b = 5.211(1), c = 8.719(2), V = 737.0(2) A3, and Z = 4. 2-Aminohydroquinone perchlorate crystallizes in the orthorhombic space group P212 121, with a = 7.110(1), b = 7.139(1), c= 18.043(4), V = 915.8(3) A3, and Z = 4. All active hydrogens of the two salts exhibit intermolecular hydrogen bonds that serve to organize a three-dimensional framework for each case.
BICYCLIC COMPOUND
-
Page/Page column 59-60, (2011/11/06)
The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
